[go: up one dir, main page]

ID26022A - Bentuk galenic pelepasan yang telah diperpanjang dan pelepasan lanjutan yang terdiri dari bahan peningkat absorpsi yang dapat diberikan melalui mulut dan penggunaan bahan peningkat absorpsi tersebut - Google Patents

Bentuk galenic pelepasan yang telah diperpanjang dan pelepasan lanjutan yang terdiri dari bahan peningkat absorpsi yang dapat diberikan melalui mulut dan penggunaan bahan peningkat absorpsi tersebut

Info

Publication number
ID26022A
ID26022A IDW20001870A ID20001870A ID26022A ID 26022 A ID26022 A ID 26022A ID W20001870 A IDW20001870 A ID W20001870A ID 20001870 A ID20001870 A ID 20001870A ID 26022 A ID26022 A ID 26022A
Authority
ID
Indonesia
Prior art keywords
materials
extension
absorption
galenic
mouth
Prior art date
Application number
IDW20001870A
Other languages
English (en)
Indonesian (id)
Inventor
Olivier Saslawski
Philippe Giet
Dominique Michel
Thierry Hulot
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ID26022A publication Critical patent/ID26022A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IDW20001870A 1998-02-23 1999-02-16 Bentuk galenic pelepasan yang telah diperpanjang dan pelepasan lanjutan yang terdiri dari bahan peningkat absorpsi yang dapat diberikan melalui mulut dan penggunaan bahan peningkat absorpsi tersebut ID26022A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9802143A FR2775188B1 (fr) 1998-02-23 1998-02-23 Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption

Publications (1)

Publication Number Publication Date
ID26022A true ID26022A (id) 2000-11-16

Family

ID=9523244

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20001870A ID26022A (id) 1998-02-23 1999-02-16 Bentuk galenic pelepasan yang telah diperpanjang dan pelepasan lanjutan yang terdiri dari bahan peningkat absorpsi yang dapat diberikan melalui mulut dan penggunaan bahan peningkat absorpsi tersebut

Country Status (27)

Country Link
US (2) US6426087B1 (fr)
EP (2) EP1056445B1 (fr)
JP (1) JP4828020B2 (fr)
KR (1) KR100587181B1 (fr)
CN (1) CN1182837C (fr)
AP (1) AP2000001943A0 (fr)
AR (2) AR018109A1 (fr)
AT (2) ATE408399T1 (fr)
AU (1) AU750785B2 (fr)
BR (1) BR9908121A (fr)
CA (1) CA2321267C (fr)
CZ (1) CZ299366B6 (fr)
DE (2) DE69917750T2 (fr)
DK (2) DK1410791T3 (fr)
ES (2) ES2314302T3 (fr)
FR (1) FR2775188B1 (fr)
HU (1) HU226732B1 (fr)
ID (1) ID26022A (fr)
NO (1) NO20004190L (fr)
OA (1) OA11454A (fr)
PL (2) PL191415B1 (fr)
PT (2) PT1410791E (fr)
RU (1) RU2228201C2 (fr)
SI (2) SI1410791T1 (fr)
SK (2) SK285188B6 (fr)
WO (1) WO1999042086A1 (fr)
ZA (1) ZA991408B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
DE10026699A1 (de) 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
SE0200475D0 (sv) * 2002-02-15 2002-02-15 Ltp Lipid Technologies Provide Oral farmaceutisk beredning
EP1499306A4 (fr) 2002-04-12 2007-03-28 Merck & Co Inc Amides bicycliques
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
FR2845289B1 (fr) * 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
CA2823937A1 (fr) * 2002-10-07 2004-04-22 Novartis Vaccines And Diagnostics, Inc. Formulations de vaccin anti-vih
US20040151769A1 (en) * 2002-12-31 2004-08-05 Boehringer Ingelheim International Gmbh Film coated tablet containing an extract of red vine leaves
ITRM20030074A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Formulazioni semisolide a rilascio immediato intese
US20040241252A1 (en) * 2003-05-29 2004-12-02 Abney Christopher Charles Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same
RU2241449C1 (ru) * 2003-09-25 2004-12-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция для лечения диабета (варианты)
WO2005060942A1 (fr) * 2003-12-19 2005-07-07 Aurobindo Pharma Ltd Composition pharmaceutique de metformine a liberation prolongee
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
BRPI0510074A (pt) * 2004-04-22 2007-10-16 Boehringer Ingelheim Int composições farmacêuticas para o tratamento de distúrbios sexuais ii
US20080181946A1 (en) * 2004-05-14 2008-07-31 Braj Bhushan Lohray Controlled Release Delivery System For Metformin
CA2569958C (fr) 2004-06-12 2016-03-22 Jane C. Hirsh Formulations de prevention des abus
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
EP1789048A1 (fr) * 2004-09-03 2007-05-30 Boehringer Ingelheim International GmbH Methode de traitement du trouble de l'hyperactivite avec deficit de l'attention
PL1796621T5 (pl) * 2004-10-01 2014-09-30 Firmenich & Cie Mikrokapsułki perfumujące lub aromatyzujące zawierające element tłumiący wybuch
WO2006096439A2 (fr) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
CA2599937A1 (fr) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Compositions pharmaceutiques permettant de traiter et/ou de prevenir les troubles de l'anxiete
US20060211685A1 (en) * 2005-03-04 2006-09-21 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
PE20061245A1 (es) * 2005-03-30 2007-01-06 Generex Pharm Inc Composiciones para la transmision transmucosa oral de la metformina
WO2006119884A2 (fr) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Methode de traitement de la toxicomanie
WO2006125041A1 (fr) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Procede pour le traitement de dysfonctionnements sexuels dus a des etats pathologiques
CA2608363A1 (fr) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Procede pour le traitement de dysfonctionnements sexuels d'origine medicamenteuse
BRPI0612752B8 (pt) * 2005-06-21 2021-05-25 Merck Patent Gmbh composição farmacêutica sólida compreendendo (r)-(-)-2-[5-(4-fluorfenil)-3-piridilmetilaminometil]cromano
EP1745788A1 (fr) * 2005-07-22 2007-01-24 KTB Tumorforschungsgesellschaft mbH Acylglycerophospholipides pour le traitement du cancer et de la cachexie
PL1912650T3 (pl) 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
CA2626134C (fr) * 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Derives de benzimidazolone utiles pour le traitement des troubles premenstruels et d'autres troubles sexuels chez la femme
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2007106957A1 (fr) * 2006-03-21 2007-09-27 Laboratoires Smb S.A. Formes galéniques flottantes multiples à libération contrôlée
EA200802208A1 (ru) * 2006-05-09 2009-04-28 Бёрингер Ингельхайм Интернациональ Гмбх Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
EP2037927B1 (fr) * 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibansérine dans le traitement de l'incontinence urinaire et des maladies associées
EP2043648A1 (fr) * 2006-07-14 2009-04-08 Boehringer Ingelheim International GmbH Utilisation de flibansérine pour le traitement de troubles sexuels chez les femmes
AR062320A1 (es) * 2006-08-14 2008-10-29 Boehringer Ingelheim Int Formulaciones de flibanserina y metodo para fabricarlas
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
WO2008022932A2 (fr) * 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Système de libération contrôlée et procédé de préparation correspondant
US20080081142A1 (en) * 2006-10-03 2008-04-03 Zeik Douglas B Articles and methods for applying color on surfaces
EP1952803A1 (fr) 2007-01-23 2008-08-06 KTB-Tumorforschungs GmbH Composition pharmaceutique solide contenant des phospholipides hydrogénés
US20090082464A1 (en) * 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US8168617B2 (en) * 2007-09-07 2012-05-01 Xenoport, Inc. Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
CL2008002693A1 (es) * 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2042165A1 (fr) * 2007-09-28 2009-04-01 Swiss Caps Rechte und Lizenzen AG Capsules molles remplies avec un excipient thermofusible
US20090099253A1 (en) * 2007-10-15 2009-04-16 Xenoport, Inc. Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
CA2638240C (fr) * 2008-08-29 2010-02-02 Alexander Macgregor Methode de traitement des anomalies de la glycemie et des variations de la glycemie
US8226967B2 (en) 2008-11-27 2012-07-24 Basf Se Surface active proteins as excipients in solid pharmaceutical formulations
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
JP5714600B2 (ja) 2009-12-18 2015-05-07 フリースランドカンピナ・ネーデルランド・ホールディング・ビー．ブイ．ＦｒｉｅｓｌａｎｄＣａｍｐｉｎａ Ｎｅｄｅｒｌａｎｄ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 共加工された錠用賦形剤混合物、その調製及び使用
JP5546900B2 (ja) * 2010-02-25 2014-07-09 ライオン株式会社 パナキサトリオール安定化組成物
CA2850468C (fr) 2010-09-28 2019-08-13 Depomed, Inc. Formes pharmaceutiques a retention gastrique pour la liberation prolongee d'acamprosate dans le tractus gastro-intestinal superieur
SG11201403785UA (en) * 2011-12-02 2014-10-30 Synchroneuron Inc Acamprosate formulations, methods of using the same, and combinations comprising the same
US20130143867A1 (en) * 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
KR20160023641A (ko) * 2013-03-15 2016-03-03 아이슈티카 인코포레이티드 아비라테론 아세테이트 제제
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
CN105431144A (zh) 2013-06-05 2016-03-23 思康脑侒股份有限公司 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
WO2017222575A1 (fr) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Procédé de préparation de formulations orales dissuasives d'abus plus stables
IL270654B2 (en) 2017-05-17 2024-07-01 Confluence Pharmaceuticals Llc Formulations of homotaurines and salts thereof
JP2024530727A (ja) 2021-08-25 2024-08-23 ビーエーエスエフ ソシエタス・ヨーロピア 直接打錠補助組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI63335B (fi) * 1979-02-02 1983-02-28 Orion Yhtymae Oy Foerfarande foer framstaellning av tabletter med foerdroejd loslighet av effektaemne
FR2457281A1 (fr) * 1979-05-23 1980-12-19 Meram Lab Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee
GB8524421D0 (en) * 1985-10-03 1985-11-06 Boots Co Plc Therapeutic agents
JPS62265226A (ja) * 1986-05-12 1987-11-18 Fujisawa Pharmaceut Co Ltd 経口投与用製剤
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
ZA898331B (en) * 1988-11-22 1990-07-25 Hoffmann La Roche Pharmaceutical compositions
US5139786A (en) * 1989-07-07 1992-08-18 Ciba-Geigy Corporation Topical formulations
JPH03275633A (ja) * 1990-03-23 1991-12-06 Teikoku Seiyaku Co Ltd 生理活性ポリペプチドの吸収促進剤
US5138786A (en) 1991-07-17 1992-08-18 Fischer Michael G Insta-guard firearm protection
IT1255895B (it) * 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
JP3275633B2 (ja) 1995-06-16 2002-04-15 松下電器産業株式会社 脱水兼用洗濯機
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon

Also Published As

Publication number Publication date
WO1999042086A9 (fr) 2000-08-31
FR2775188A1 (fr) 1999-08-27
NO20004190D0 (no) 2000-08-22
SI1056445T1 (en) 2004-10-31
BR9908121A (pt) 2000-10-24
EP1410791B1 (fr) 2008-09-17
CA2321267C (fr) 2007-04-17
SK285188B6 (sk) 2006-08-03
OA11454A (en) 2003-12-08
ES2222695T3 (es) 2005-02-01
HU226732B1 (en) 2009-08-28
DK1410791T3 (da) 2009-01-12
HUP0100970A3 (en) 2001-12-28
HK1035142A1 (en) 2001-11-16
KR20010034537A (ko) 2001-04-25
US6514524B1 (en) 2003-02-04
DK1056445T3 (da) 2004-10-04
HUP0100970A2 (hu) 2001-08-28
US6426087B1 (en) 2002-07-30
DE69939605D1 (de) 2008-10-30
DE69917750T2 (de) 2005-05-25
PL191415B1 (pl) 2006-05-31
PL342162A1 (en) 2001-05-21
AR018109A1 (es) 2001-10-31
PT1056445E (pt) 2004-10-29
AU750785B2 (en) 2002-07-25
WO1999042086A1 (fr) 1999-08-26
EP1410791A1 (fr) 2004-04-21
ZA991408B (en) 1999-08-23
RU2228201C2 (ru) 2004-05-10
SK12552000A3 (sk) 2001-02-12
SI1410791T1 (sl) 2009-02-28
FR2775188B1 (fr) 2001-03-09
PL201851B1 (pl) 2009-05-29
ATE408399T1 (de) 2008-10-15
CZ299366B6 (cs) 2008-07-02
KR100587181B1 (ko) 2006-06-08
ES2314302T3 (es) 2009-03-16
NO20004190L (no) 2000-10-20
AU3140899A (en) 1999-09-06
JP2002503686A (ja) 2002-02-05
ATE268164T1 (de) 2004-06-15
EP1056445B1 (fr) 2004-06-02
JP4828020B2 (ja) 2011-11-30
EP1056445A1 (fr) 2000-12-06
CA2321267A1 (fr) 1999-08-26
CZ20002940A3 (cs) 2000-11-15
CN1291091A (zh) 2001-04-11
AR066843A2 (es) 2009-09-16
CN1182837C (zh) 2005-01-05
SK286248B6 (sk) 2008-06-06
PT1410791E (pt) 2008-12-24
DE69917750D1 (de) 2004-07-08
AP2000001943A0 (en) 2000-12-31

Similar Documents

Publication Publication Date Title
ID26022A (id) Bentuk galenic pelepasan yang telah diperpanjang dan pelepasan lanjutan yang terdiri dari bahan peningkat absorpsi yang dapat diberikan melalui mulut dan penggunaan bahan peningkat absorpsi tersebut
ID26876A (id) Derivat-derivat benzotiepin 1,1-dioksida, proses pembuatannya, bahan-bahan farmasi yang terdiri dari senyawa-senyawa ini dan penggunaannya
ID21314A (id) Komposisi pembersih dan disinfektan yang dapat didegradasi dalam air, padat, dan metoda-metoda gabungan dari pembuatan dan penggunaannya
PL354315A1 (pl) Kompozycja kosmetyczna lub farmaceutyczna w postaci ciała stałego zawierająca bis-acyloamidy
EP1598897A4 (fr) Agent d'etancheite pour element de conversion photoelectrique et element de conversion photoelectrique l'utilisant
ID30393A (id) Senyawa tienopirimidina, pembuatan dan penggunaannya
ID22889A (id) Komposisi kopolimer etilena dan penggunaannya
HUP0303103A3 (en) Fused pyrrolocarbazoles, pharmaceutical compositions containing them and use of the compounds
TWI316062B (en) Anti-inflammatory compounds and uses thereof
DE60042486D1 (de) Resonatorstruktur und dieselbe enthaltendesfilter
EP1426027A4 (fr) Composition et preparation cosmetique contenant ladite composition
HUP0104496A3 (en) Compositions comprising 1,1,1,3,3-pentafluorobutane and use of said compositions
IL155196A0 (en) Benzamide derivatives and pharmaceutical compositions containing the same
NO20025004L (no) Fremgangsmåte for fremstilling av 2,5-diketopiperaziner, 2,5- diketopiperaziner, dipeptider samt anvendelse derav
DE69928260D1 (de) Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
ID27922A (id) KOMPOSISI FARMASETIKAL DAN PENGGUNAAN DARI ANDROST-5-ENA-3β, 17β-DIOL
AU8179201A (en) The use of resveratrol as sunscreen
ID26402A (id) Amida-amida tersubstitusi yang baru, pembuatan dan penggunaannya
ID26945A (id) Komposisi farmasi yang mengandung misel yang terdiri dari glukokortikosteroid lipofilik dan hanya satu surfaktan
AU1080901A (en) Catalyst compositions employing sol particles and methods of using the same
ID26279A (id) Film pengemas dan penggunaan film pengemas tersebut
PL366851A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
IL156161A0 (en) Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors
DE60017614D1 (de) Ultraschallreiniger und diesen enthaltende Nassbehandlungsdüse
DE60022828D1 (de) Kosmetikeinheit und deren Zusammensetzung